After the success of the first trial of the bird-flu vaccine on humans, China is all set to conduct the second trial for which it requires 400 volunteers. The second stage of the trial will focus on measuring the duration of protection afforded by the vaccine in the human body against the lethal H5N1 strain. It is required that the vaccine undergoes three phases of trial before being considered safe for administration.
In the first round, nearly 120 people got the vaccination shots, which did not trigger any adverse reaction, except for mild fever in few cases, an acceptable reaction to any vaccine.
Advertisement
The trial would require volunteers between the ages of 18 to 65, but people older than 65 or pregnant women will not be allowed to participate in the trial.
The vaccine developed by Sinovac Biotech Limited and the Ministry of Science and Technology and the Center for Disease Control and Prevention, has plans of enlarging the capacity of their production unit, to enable huge quantities of human bird-flu vaccine, after the envisaged two rounds of trials prove successful.
Source: Medindia
SAV
Source: Medindia
SAV
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Bird Flu News
In environments where avian influenza virus may be present, the WHO advises regular hand washing and good food safety and food hygiene practices.
Bird flu in Israel: Nearly 7,300 infected turkeys were detected in the village of Hatzor, while another 9,500 in the village of Ein Tzurim.
In the US, four red baby foxes died due to the devastating bird flu H5N1 detected in wild mammals. Highly pathogenic avian influenza is highly contagious.
The first known human case of H5 bird flu in a person has been reported in Colorado, the Centers for Disease Control and Prevention (CDC) announced.
In India, bird flu has resurfaced with cases from Maharashtra's Thane and Palghar regions. An expert said bird flu is unlikely to spread majorly in the country.